Preconditioning with Soluble Guanylate Cyclase Activation Prevents Postischemic Inflammation and Reduces Nitrate Tolerance in Heme Oxygenase-1 Knockout Mice
Overview
Physiology
Affiliations
Previously we have shown that, unlike wild-type mice (WT), heme oxygenase-1 knockout (HO-1-/-) mice developed nitrate tolerance and were not protected from inflammation caused by ischemia-reperfusion (I/R) when preconditioned with a H2S donor. We hypothesized that stimulation (with BAY 41-2272) or activation (with BAY 60-2770) of soluble guanylate cyclase (sGC) would precondition HO-1-/- mice against an inflammatory effect of I/R and increase arterial nitrate responses. Intravital fluorescence microscopy was used to visualize leukocyte rolling and adhesion to postcapillary venules of the small intestine in anesthetized mice. Relaxation to ACh and BAY compounds was measured on superior mesenteric arteries isolated after I/R protocols. Preconditioning with either BAY compound 10 min (early phase) or 24 h (late phase) before I/R reduced postischemic leukocyte rolling and adhesion to sham control levels and increased superior mesenteric artery responses to ACh, sodium nitroprusside, and BAY 41-2272 in WT and HO-1-/- mice. Late-phase preconditioning with BAY 60-2770 was maintained in HO-1-/- and endothelial nitric oxide synthase knockout mice pretreated with an inhibitor (dl-propargylglycine) of enzymatically produced H2S. Pretreatment with BAY compounds also prevented the I/R increase in small intestinal TNF-α. We speculate that increasing sGC activity and related PKG acts downstream to H2S and disrupts signaling processes triggered by I/R in part by maintaining low cellular Ca²⁺. In addition, BAY preconditioning did not increase sGC levels, yet increased the response to agents that act on reduced heme-containing sGC. Collectively these actions would contribute to increased nitrate sensitivity and vascular function.
Inflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction.
Daou D, Gillette T, Hill J Physiology (Bethesda). 2023; 38(5).
PMID: 37013947 PMC: 10396273. DOI: 10.1152/physiol.00004.2023.
Cellular and molecular pathobiology of heart failure with preserved ejection fraction.
Mishra S, Kass D Nat Rev Cardiol. 2021; 18(6):400-423.
PMID: 33432192 PMC: 8574228. DOI: 10.1038/s41569-020-00480-6.
Liu Y, Wang M, Wang D, Fay W, Korthuis R, Sowa G Am J Physiol Heart Circ Physiol. 2021; 320(3):H1185-H1198.
PMID: 33416452 PMC: 8362680. DOI: 10.1152/ajpheart.00682.2020.
Higashi Y, Sukhanov S, Shai S, Danchuk S, Snarski P, Li Z Am J Physiol Heart Circ Physiol. 2020; 319(4):H730-H743.
PMID: 32795184 PMC: 7654661. DOI: 10.1152/ajpheart.00064.2020.
Ferreira Jr W, Chweih H, Lanaro C, Almeida C, Brito P, Gotardo E J Pharmacol Exp Ther. 2020; 374(3):469-478.
PMID: 32631869 PMC: 7445859. DOI: 10.1124/jpet.119.264606.